openPR Logo

Press Releases from Protagen AG (9 total)

Protagen and Charles River form strategic partnership

Dortmund, Germany, October 28, 2011. Protagen AG, Dortmund, a GMP-certified specialist in the characterization of protein drugs and Charles River Laboratories International, Inc., one of the world leading companies in high-quality research models and preclinical and clinical support services, are pleased to announce a strategic Marketing & Sales alliance. For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range

Protagen and OncoTyrol form strategic alliance to validate the UNIarray® techno …

Dortmund, Germany and New Jersey, USA, June 10, 2009. Protagen AG and the Medical University Innsbruck, Department of Urology, have recently identified autoantigen candidates present in serum of patients with prostate cancer using the proprietary UNIArray® technology platform. In Europe, prostate cancer is the second most frequent lethal malignancy in men. Yearly about 40,000 men die of prostate cancer in the European Union. Current standard of screening for prostate

Protagen meets with FDA

Dortmund, Germany and New Jersey, USA, February 19, 2009. Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips announces that it participated in two meetings with FDA personnel during the week of January 26, 2009. The meetings were intended to provide a detailed introduction to the company’s UNIarray® technology position and its potential use in the development of novel diagnostics for multiple sclerosis

Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technol …

Dortmund, Germany and New Jersey, USA, December 3, 2008. Protagen AG announces the closing of a cooperation contract with Bayer HealthCare AG, Leverkusen, Germany, about the evaluation of the UNIarray® technology for discovery of novel biomarkers in atrial fibrillation. Bayer HealthCare is currently investigating atrial fibrillation after heart surgery in a clinical study. A certain number of patients develop this type of cardiac symptoms after surgery. Currently, it is not possible

Winner Consortium “NeuroAllianz” in the BioPharma Competition counts on UNIa …

Dortmund, Germany and New Jersey, USA, October 9, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips has won the BMBF’s BioPharma competition jointly with consortium “NeuroAllianz”. The twelve project partners will develop therapeutic as well as diagnostic approaches in the field of neurodegenerative diseases from bench to market under the direction of Professor Christa E. Mueller and Professor Alexander Pfeifer. Protagen

Protagen closes new round of financing to strengthen technology position for nov …

Dortmund, Germany and New Jersey, USA, August 1, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips announces the closing of a new round of financing. The capital will be used to strengthen and expand the company’s UNIarray® technology position and the development of novel diagnostics. The capital raised in this round has come from the existing institutional investors, MIG AG, Munich,

Protagen and GeneBio Sign Distribution Agreement for Modiro®

Dortmund, Germany and Geneva, Switzerland – May 29, 2008 - Protagen AG and Geneva Bioinformatics (GeneBio) SA today announced a distribution agreement that allows GeneBio to distribute Protagen’s Modiro, a novel software tool enabling rapid and automated detection of true post-translational modifications in MS/MS datasets. Under the terms of the agreement, GeneBio will distribute the Modiro package on a global basis; at the same time, GeneBio and Protagen will collaborate closely

UNIchip protein biochips from Protagen identify significant off-target binding f …

Findings could explain side effects seen with these biological drugs for treating rheumatic diseases Dortmund, Germany and New Jersey USA, 31 March 2008: Tumor Necrosis Factor (TNF)-α inhibitors used to treat rheumatic diseases may bind to a significant number of proteins other than their main target, according to the results of an in vitro study published in Analytical and Bioanalytical Chemistry. This off-target binding activity might explain some of the side

direct/ Protagen AG closes second round of financing with old and new investors

The MIG AG Funds 1 and 3 in Munich are investing into Protagen AG. In cooperation with the co-investor S-Venture Capital Dortmund GmbH, Euro 3,3 Million will be invested into Protagen AG. Protagen AG has successfully switched from a fee-for-service company to a product company. By introducing the protein biochip products UNIchip® AV-400 and UNIchip® AV-VAR customers from the entire biotech and pharmaceutical industry can profit from safer and more efficient

Go To Page:   1 2 3 4 5 6 7 8 9 10